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Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in
familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic
features of AIPmut-associated pituitary adenomas have not been studied comprehensively.
Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut
pituitary adenomas.
Design: This study was an international, multicenter, retrospective case collection/database analysis.
Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments.
Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232
matched AIPmut-negative acromegaly controls.
Results: The AIPmut population was predominantly young and male (63.5%); first symptoms oc-
curred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%);
extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there
were also prolactinomas (n 13), nonsecreting adenomas (n 7), and a TSH-secreting adenoma.
AIPmut somatotropinomas were larger (P  0.00026), with higher GH levels (P  0.00068), more
frequent extension (P  0.018) and prolactin cosecretion (P  0.00023), and occurred 2 decades
before controls (P 0.000001). Gigantismwasmore common in theAIPmut group (P 0.000001).
AIPmut somatotropinoma patients underwent more surgical interventions (P 0.00069) and had
lower decreases in GH (P  0.00037) and IGF-I (P  0.028) and less tumor shrinkage with soma-
tostatin analogs (P  0.00001) vs. controls. AIPmut prolactinomas occurred generally in young
males and frequently required surgery or radiotherapy.
Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treat-
ment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting,
suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. (J Clin
Endocrinol Metab 95: E373–E383, 2010)
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Pituitary adenomas occur relatively frequently and theprevalence of clinically apparent pituitary adenomas
is one in 1064–1289 of the general population (1, 2). Al-
though almost universally benign, pituitary tumors are
associated with a heavy clinical burden due to a combi-
nationof local compressive symptoms, the systemic effects
of hormonal hypersecretion, and the need for neurosur-
gery, chronicmedical therapy,or radiotherapy.Hence, the
molecularpathophysiologyunderlyingpituitary adenoma
formation has been the subject of extensive research.
Mutations inmultiple oncogenes and tumor suppressor
genes have been associated with a role in pituitary tumor-
igenesis (3). The best characterized of these include gsp,
PTTG, andMEG3 among others (3–5). These are gener-
ally noted as somatic mutations in tumor specimens after
surgery. In contrast, very few germline genetic mutations
that are implicated in inherited pituitary tumor risk are
known. Multiple endocrine neoplasia (MEN) type 1 and
Carney complex (CNC) are the best-described familial pitu-
itary tumorsyndromes (6,7).MEN4isanewer, rareMEN1-
like syndrome caused by germline mutations in the
CDKN1B gene (8). MEN1 and CNC can be screened for
genetically to identify at-risk carriers and potentially diag-
nosetumors,pituitaryorothers,atanearlierstage.However,
themolecular pathophysiology of pituitary adenomas is less
clear in many other families, such as kindreds with familial
isolated pituitary adenomas (FIPA) (9).
Recently interest has turned to the identification of new
genes associated with familial pituitary adenomas. In
2006 Vierimaa et al. (10) reported that mutations in the
aryl hydrocarbon receptor interacting protein gene (AIP)
conferred a pituitary adenoma predisposition in familial
pituitary adenoma kindreds in Finland and Italy. Since then,
extensive studies have identified many AIP mutations
(AIPmut) in familial and sporadic pituitary adenomas
(11–17).AIPmutaccount for 15%ofFIPAkindreds (50%
of those with homogeneous familial somatotropinomas)
and are associatedwith somatotropinomas, prolactinomas,
nonsecreting adenomas, and rare cases of Cushing disease
(11, 12, 18).
To date, studies have concentrated largely on the issue
ofAIPmutprevalence amongvarious patient populations.
There have been indications of relatively aggressive dis-
ease features in pituitary adenoma patients with AIPmut
(10, 11, 17, 19), but clinical aspects have not been studied
specifically in a standardized fashion. Therefore, we under-
took a standardized, comprehensive analysis of a large in-
ternational cohort of patients with AIPmut and pituitary
adenomas to determine the demographic, hormonal, radio-
logical, and therapeutic characteristics of these patients.
Subjects and Methods
This was an international collaborative study to determine the
clinical characteristics and responses to therapy in patients with
AIPmut-associated pituitary adenomas. The collaboration in-
volved 36 centers in Belgium, Finland, France, Italy, Spain, Ger-
many, Bulgaria, The Netherlands, Brazil, Argentina, the United
States, Australia, New Zealand, and Lebanon. This study in-
cluded pituitary adenoma patients without MEN1, MEN4, or
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CNC that were diagnosed withAIPmut from 2006 to 2009 and
were originally diagnosedwith pituitary adenomas between Jan-
uary 1, 1970, and December 31, 2009. The only selection cri-
terion was a willingness to undergo genetic studies after provi-
sion of informed consent, and the population was not otherwise
selected by uniform criteria such as age, sex, tumor type/char-
acteristics, or responses to therapy (1727 patients consented to
take part). AIP genetic studies were performed using leukocyte
DNA extracted from peripheral blood as described by Vierimaa
et al. (10); multiplex ligation-dependent probe amplification stud-
ies were performed as described previously (13, 20). Normal pop-
ulation genetic databases were assessed for the presence of AIP
polymorphisms. All patients and controls (see below) provided in-
formed written consent for genetic testing at their center in their
local language, and the studywas approved by the Ethics Commit-
tee of the Centre Hospitalier Universitaire of Lie`ge.
Clinical and therapeutic data were collected de novo using
standardized data collection under predefined criteria for all pa-
tients at all participating study centers (see Supplemental Mate-
rial, published on The Endocrine Society’s Journals Online web
site at http://jcem.endojournals.org). Anonymized patient infor-
mation on demographics, diagnosis, genetics, hormonal profiles
at diagnosis, and radiological criteria were collected. Therapeu-
tic responses for each patient after neurosurgery, somatostatin
analog (SSA) therapy, radiotherapy, dopamine agonists, and
pegvisomant were collected and tabulated. Long-term responses
to therapy were collated for patients treated for 12 months or
longer after initial treatment and included information on hor-
monal, clinical, and radiological disease status; treatment mo-
dalities used; and the presence of hypopituitarism. Tumor size
was measured as the maximum diameter on computed tomog-
raphy ormagnetic resonance imaging and tumorswere classified
accordingly as microadenomas (10 mm) or macroadenomas
(10 mm); giant adenomas were tumors measuring 40 mm or
greater in maximum diameter. Information on extrasellar ex-
tension and invasion of surrounding structures were also col-
lected in all available instances from radiological reports or from
surgical notes. Diagnosis of gigantism was verified in patients
with current/previous evidence of abnormal, progressive, and
excessively rapid growth velocity for age, a height greater than 2
SD scores above normal for their population (i.e. 95th percen-
tile) and height greatly (5 cm) in excess of the calculated mid-
parental height in the absence of constitutional tall stature
(21–23).
Long-term disease control criteria (12months of follow-up
after therapy) were defined according to tumor type. In all cases
tumor size had to be stable without growth or expansion. For
patients with somatotropinomas, control at last follow-up was
defined as the absence of clinical activity, an age/sex-appropriate
IGF-I that was at the upper limit of normal (ULN) or less for the
assay used and a valid random GH level less than 1 ng/ml at last
follow-up. In prolactinoma cases, serum prolactin had to be at the
ULNor less for the assayused. Fornonsecreting-adenomas, disease
controlwasdefined as long-term tumor size stability; in thyrotropi-
noma cases, patients had to be symptom free and have serumTSH,
T4, and T3 levels within normal limits.
Control population
Previous studies reported thatAIPmut are predominantly as-
sociated with somatotropinomas (10, 11, 12, 17, 19, 20). A
suitable control population database ofAIPmut-negative soma-
totropinoma patients was developed de novo to compare demo-
graphic, clinical, and therapeutic features. The control database
comprised298non-MEN1,non-CNCacromegalypatients from
the collaborating study centers.All patients hadnormal germline
AIP gene sequences. Anonymized demographic, clinical, and
therapeutic data and long-term outcomes were collected on con-
trol patients using identical criteria used for theAIPmutpatients.
To minimize potential bias due to variations in treatment prac-
tice amongcenters andover time, the control groupwas stratified
according to decade of diagnosis and geographic region (north-
ern Europe, southern Europe/Mediterranean, North America,
South America, and Oceania). Control patients were then ran-
domly extracted to match the AIPmut group in terms of decade
of diagnosis and geographic region to give a proportion of three
or more control cases for each AIPmut case. This final stratified
control group used for comparative purposes consisted of 232
AIPmut-negative somatotropinoma patients.
Predefined comparisons between theAIPmut and the control
group were performed on the following disease and treatment
characteristics: gender ratio, ages at diagnosis and at first symp-
toms, tumor size and classification, proportion of patients with
extrasellar extension and invasion, GH and IGF-I levels at base-
line, prolactin cosecretion at baseline, treatment characteristics
(number/type of surgery, use of radiotherapy, hormonal and ra-
diological responses to medical therapies), proportions of pa-
tients with controlled and active disease, disease control as a
function of cumulative therapies, and frequency of hypopitu-
itarism among patients with controlled and active disease.
Statistics
Continuous data were represented as medians and ranges.
Because data were nonnormally distributed, comparisons were
made using a nonparametric test (Wilcoxon’s signed rank test).
For count data, values were placed in a contingency table and
compared with a 2 test. Where continuous data were plotted as
density graphs, a kernel density approximation was computed
using a Gaussian kernel, and bandwidth was calculated using
Silverman’s rule of thumb. The kernel densitywas finally plotted
as a continuous curve. All statistical analyses were performed
using the R statistical package, version. 2.7.0 (R Development




The study population comprised 96 patients withAIP-
mut and pituitary adenomas. There were 43 separateAIP
mutations; 54.2% of patients had mutations leading to
premature stop codons causing protein truncation,
whereas a further 31.3% had missense mutations. Most
patients presented in FIPA kindreds (59.4%), 10.4% had
a familial AIPmut and no known relatives with pituitary
adenomas, and 29 patients (30.2%) were apparently spo-
radic cases.
Clinical characteristics
Demographic and clinical features of the AIPmut co-
hort and each tumor subgroup are shown in Table 1. The
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population was predominantly male (63.5%) and the age
at diagnosis was young. Themedian age at first symptoms
of 18.0 yr indicates half the patients were children or ad-
olescents at clinical onset. Tumors were overwhelmingly
macroadenomas (93.3%), were large (12 were giant adeno-
mas), and 56.3% had invaded local structures at diagnosis.
No statistically significant differences existed between char-
acteristics in male and female patients with AIPmut.
Analyses by tumor type
Somatotropinomas
Somatotropinomas were the predominant tumor type
associated with AIPmut with 75 patients (78.1% of the
cohort); 34 separate mutations were noted. The AIPmut
somatotropinoma group (Table 2) was mainly male
(61.3%), and there was a significantly higher male to fe-
male ratio than controls (P  0.027). The median age at
first symptoms was 20.5 yr earlier in AIPmut soma-
totropinoma patients vs. controls (P  0.000001); first
symptomsoccurred as childrenor adolescents in 52.2%of
the AIPmut cohort as compared with only 4.3% of con-
trols (Fig. 1). Similarly, theAIPmut cohort was diagnosed
nearly 2 decades before mutation-negative controls (P 
0.000001; Fig. 1). Gigantism was significantly more fre-
quent in theAIPmut cohort than controls (P0.000001);
all 24 patients with gigantism in the AIPmut group were
males as comparedwith five of 15 patients with gigantism
in the control group who were female.
Median maximum tumor diameter was larger (P 
0.00026; Fig. 2), and the proportion of patients withmac-
roadenomas was higher in the AIPmut group vs. controls
(P  0.026; Table 2); 9.3% of tumors were giant adeno-
mas in the AIPmut group as compared with 1.3% among
controls. There was a higher frequency of extrasellar ex-
tension (P  0.018) and a trend toward more frequent
invasion of local structures in the AIPmut cohort vs. con-
trols. Larger tumor size in the AIPmut group was associ-
ated with significantly higher median levels of GH at di-
agnosis than controls (P 0.00068; Fig. 3); median IGF-I
levels did not differ (P  0.48). Cosecretion of GH and
prolactin was nearly twice as frequent in the AIPmut
group as in controls (P  0.00023).
Treatment of patients was multimodal in 61.3 and
66.4% of the AIPmut cohort and control cases, respec-
tively. The proportions of patients that received various
combinations of different treatment modalities were the
same in both groups. The median duration of follow-up
after diagnosiswas similar in the two groups [AIPmut: 9.0
yr (range 1.0–38.5 yr); control: 9.5 yr (range 0.5–34.5
yr)]. Follow-upperiods after diagnosis and after treatment
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Among71AIPmut somatotropinomapatientswithmore
than 12 months of follow-up, control was achieved in 50
cases (70.4%) and acromegaly remained active in 21 cases
(26.8%). The long-term disease control rate was higher in
control patients (182 of 226; 80.5%), but this was not sta-
tistically significant (P  0.06). Among the patients with a
higher cumulative treatment burden (three or more distinct
modalities), long-term disease control rates were signifi-
cantly poorer in the AIPmut group vs. controls [15 of 27
(55.6%) vs. 63 of 76 (82.9%), respectively; P 0.01].
Similar proportions of patients had pituitary neurosur-
gery in theAIPmut (87.3%) and control groups (80.5%);
reoperationwas significantlymore frequent in theAIPmut
group than the controls (21.9 vs. 5.5%, respectively; P
0.00069). There was a trend toward more frequent use of
radiotherapy in the AIPmut group than in controls (41.4
vs. 24.7%, respectively; P 0.15). Percentage reductions
in GH and IGF-I were similar for primary, pre-, and post-
operative SSAusewithin each group. In theAIPmut group
(n  38), the median SSA-induced reductions in GH
[40.0% (range 0.0–99.0%)] and IGF-I [47.4% (range
0.0–83.4%)] were significantly lower than those seen in
the 164 control patients treated with long-term SSA [GH:
75.0% (range 0.0–99.0%); P  0.0004; IGF-I: 56.0%
(range 0.0–100.0%);P 0.028)]. Themedianmagnitude
of tumor shrinkage achieved with SSA was significantly
higher in the control group [median 41.1% (range 0.0–
95.0%)] vs. AIPmut patients [0.0% (range 0.0–90.0%);
P  0.000001]. The disease control rates achieved with
SSA in theAIPmut and control groups, respectively, were
as follows: primary treatment (one of six vs. 17 of 32);
preoperative (one of six vs. six of 16) and postoperative
(nine of 26 vs. 51 of 84). Concomitant radiotherapy use
was similar among patients whowere controlled vs. those
not controlled by SSA in the two groups. Four cases, all in
the AIPmut group, had complete postoperative SSA re-
sistance with increasing GH/IGF-I levels; tumor expan-
sion during SSA therapy occurred in three of these cases.
Unlike in theAIPmut group inwhich three of four patients
were uncontrolled by pegvisomant therapy, all 19 control
acromegaly patients who received pegvisomant had con-
trolled IGF-I levels at follow-up.
The frequency of hypopituitarism was similar in the
AIPmut and control groups (22.5 vs.25.2%), but theAIP-
mut group had a significantly higher number of deficient
axes than controls patients (P  0.000001).
Prolactinomas
There were 13 patients with AIPmut and prolactino-
mas in the cohort, nine of whom have not been reported
previously. Seven patients came from FIPA kindreds, two
had familialmutationswithoutotherknownaffected fam-
ily members, and four were apparently sporadic cases.
Most patients were male (76.9%; Table 1). Patients had
young median ages at first symptoms (18.0 yr) and diag-
nosis (22.0 yr), and median prolactin levels at diagnosis
were high (2520.0 ng/ml; range 74.0–60,000.0 ng/ml).
Median maximum tumor diameter was large (31.0 mm;
range 6.0–85.0 mm), 12 of 13 tumors were macroadeno-
mas, 11 of these had extrasellar extension and nine were
invasive at diagnosis.
All but one patient received primary dopamine agonist
therapy,whichwasassociatedwith reductions frombaseline
in prolactin of 50–99%. Initial normalization of prolactin
secretion occurred in five cases (maximum cabergoline dose
2.5 mg/wk); one further patient later developed secondary
dopamineagonist resistanceand tumorgrowthdespitehigh-
dose cabergoline (7 mg/wk). Two transsphenoidal surgeries
TABLE 2. Comparisons between clinical characteristics at diagnosis of AIPmut-associated and non-AIPmut
somatotropinoma groups
Somatotropinoma group
AIPmut (n  75) Control (n  232) P value
Sex ratio (male/female) 1.6 0.87 0.027
Age at diagnosis (yr) 22.0 (8.0–60.0) 43.0 (16.0–72.0) 0.000001
Age at first symptoms (yr) 17.5 (4.0–50.0) 38.0 (14.0–70.0) 0.000001
Maximum tumor diameter (mm) 22.5 (7.0–60.0) 16.0 (3.0–48.0) 0.00026
Macroadenoma 93.1 80.8 0.026
Extrasellar extension (%) 65.1 49.8 0.018
Invasion (%) 51.7 38.8 0.11
GH level at diagnosis (ng/ml) 28.5 (3.3–183.0) 17.4 (1.7–180.0) 0.00068
IGF-I level at diagnosis (% ULN) 217.0 (116.0–1090.0) 210.5 (20.0–550.0) 0.48
Prolactin cosecretion (%) 56.1 28.9 0.00023
Gigantism (%) 32.0 6.5 0.000001
Extrasellar extension was defined as clearly visible superior or lateral extension of the tumor beyond the sellar borders on radiological imaging or at
surgery. Invasion was defined as radiological, surgical, or pathological evidence of the presence of pituitary tumor tissue invading or penetrating
the structures forming the normal border of the pituitary gland. Age at diagnosis, age at first symptoms, delay in diagnosis, maximum tumor
diameter, and GH and IGF-I levels at diagnosis are presented as median (ranges).
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plus radiotherapywas needed to achieve disease control. Six
patients (50%) were initially uncontrolled with dopamine
agonists and underwent surgery, one of whom underwent
three transsphenoidal and one transcranial interventions
plus radiotherapy, whereas another two patients had two
surgical interventionseach.Radiotherapywaseventuallyun-
dertaken in three operated patients. Long-term control of
prolactin secretion was achieved in eight of 13 patients
(61.5%) and two patients developed hypopituitarism.
Nonsecreting adenomas
Seven nonsecreting pituitary adenomas occurred in pa-
tients (four males, three females) with AIPmut, and all
came from FIPA kindreds. The median age at diagnosis
FIG. 1. Significantly younger age at diagnosis (A and C) and age at first symptoms (B and D) in somatotropinoma patients with AIPmut (n  71)
and control somatotropinoma patients (n  232). A and C, Frequency plot curves of ages at diagnosis and first symptoms for the two groups. B
and D, Box and whisker plots in which the box represents the 25th and 75th percentiles, and the dark line within the box is the median. The
whiskers represent the extremes of data that lie one box length distance above and below the 25th and 75th centiles, respectively.
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was younger than commonly described for this disease
[31.0 (range 12.0–74.0 yr)] (24). All tumors were mac-
roadenomas, six had suprasellar extension and four were
invasive at diagnosis. Two patients presented with pituitary
apoplexy. All patients hadmildly elevated prolactin at diag-
nosis, and in three patientswho receiveddopamine agonists,
two achieved normal prolactin (no tumor shrinkage). At
diagnosis, one patient had hypogonadism and one had
FIG. 3. Significantly greater GH level at diagnosis in somatotropinoma patients with AIPmut (n  71) and control somatotropinoma patients (n 
232). A, A frequency plot curve. B, Box and whisker plot in which the box represents the 25th and 75th percentiles, and the dark line within the
box is the median. The whiskers represent the extremes of data that lie one box length distance above and below the 25th and 75th centiles,
respectively.
FIG. 2. Significantly greater maximum tumor diameter in somatotropinoma patients with AIPmut (n  71) and control somatotropinoma patients
(n  232). A, A frequency plot curve. B, Box and whisker plot in which the box represents the 25th and 75th percentiles, and the dark line within
the box is the median. The whiskers represent the extremes of data that lie one box length distance above and below the 25th and 75th centiles,
respectively.
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hypofunction of the cortisol, thyroid, and gonadal axes,
which did not resolve after therapy. Six patients under-
went surgery and one patient who underwent a transcra-
nial approach received radiotherapy due to a large rem-
nant. Long-term control of tumor size was achieved in all
cases.
TSH-secreting adenoma
A39-yr-oldmale patient presentedwith a 6-month his-
tory of tachycardia and breathing difficulties in associa-
tion with elevated T3 and T4 levels, a normal TSH level,
and had a noninvasive pituitary macroadenoma on mag-
netic resonance imaging. No other hormonal abnormali-
ties were noted at diagnosis. The patient twice underwent
transsphenoidal surgery, but the tumor regrew on both
occasions within less than 1 yr. A missense AIPmut
(I257V) was discovered; family screening identified the
same mutation in the unaffected mother and brother. Af-
ter the second tumor recurrence, the patient was treated
with octreotide long-acting repeatable 20 mg/month,
which resulted inahormonalnormalizationbutnochange
in the residual tumor size.
Genotype-phenotype relationships
There were no statistical differences in terms of the
clinical or therapeutic characteristics among patients with
different types of AIPmut (truncating, frameshift muta-
tions,missensemutations, intronicmutations, or in-frame
deletions). The characteristics of the three most frequent
AIP mutations, Q14X (n  13), R304X (n  8), and
R271W (n 7), did not differ from the group as a whole.
Discussion
In this studywe report the clinical and therapeutic features
in 96 patients with germline AIPmut and anterior pitu-
itary adenomas in the setting of FIPA and sporadic disease
(10–13, 16, 20, 39, 41, 47, and Supplemental Material
Refs. 1 and 2); 41 patients are reported for the first time.
This study is the first to apply standardized data collection
methods to an extensive international AIPmut cohort to
assess clinically relevant patient and disease characteris-
tics, including responses to therapy.
The spectrum of anterior pituitary tumors associated
with AIPmut now includes all clinical subtypes. Nearly
80% of patients with AIPmut present with somatotropi-
nomas, andmore than half cosecrete GH and prolactin. A
third of somatotropinoma patients in the AIPmut group
had gigantism. A further 13.5% of patients had prolacti-
nomas, whereas nonsecreting pituitary adenomas are
clearly alsoa featureof theAIPmut spectrum.TheAIPmut
TSH-secreting tumor is the first to be reported; because
these are rare tumors (1% of all pituitary tumors), it
remains to be seen whether AIPmut is frequent in this
setting (25).Cushing disease is a very rare associationwith
AIPmut, with only two cases in the literature and none in
the current series (12, 18).
The reason for thepredominanceof somatotropinomas
amongpatientswithAIPmut is unclear; however, this sub-
group has specific features comparedwith awell-matched
internationalAIPmut-negative control somatotropinoma
group. AIPmut-associated somatotropinomas had first
symptoms and were diagnosed 20 yr earlier as compared
with controls and were significantly larger, more fre-
quently extensive and had a greater frequency of prolactin
hypersecretion. In addition,AIPmut status was also asso-
ciated with significantly higher levels of GH secretion at
baseline vs. controls. These features also appeared to im-
pact the therapeutic responses, with poorer disease out-
comes in theAIPmutgroup.Large, extensive, and invasive
macroadenomas and high GH secretion are associated
with a lower rate of control with primary neurosurgery;
hence, the significantly higher rate of reoperation in the
AIPmut cohort is not surprising (26). In addition, SSA
therapy was associated with significantly lower decreases
from baseline in GH and IGF-I in the AIPmut group,
whereas tumor shrinkage was also significantly less pro-
nounced than in controls. A trend toward more frequent
use of radiotherapy and the failure of pegvisomant to con-
trol IGF-I in three of four individuals in theAIPmut group
(as compared with 19 of 19 controlled pegvisomant-
treated sporadic patients) lends further evidence to AIP-
mut patients forming a challenging part of the therapeutic
spectrum in acromegaly. This is supported by the finding
that AIPmut somatotropinoma patients who received
similarly high (3) cumulative numbers of therapies had
significantly lower rates of long-term disease control as
compared with the somatotropinoma control group. The
reason for the poorer responses to SSA is not known and
is a compelling topic for further study, particularly be-
cause SSA receptor expression and the activity of vital
determinants of SSA function like the ZAC1 (zinc finger
protein which regulates apoptosis and cell cycle arrest)
(27), inAIPmut somatotropinoma cells remain unknown.
Practically itmaybe that large tumor size and the relatively
poor SSA responses in such cases might warrant a tumor
debulking approach to favor eventual control with SSA
(28, 29).
Gigantism is an integral but very rare component of the
acromegaly disease spectrum, with little more than 100
cases reported (30–34). Gigantism may occur exception-
ally in other conditions like MEN1, CNC, or McCune-
Albright syndrome (30). In contrast, the current results
suggest that gigantism is a frequent findingamongpatients
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withAIPmut,with 32%of allAIPmut somatotropinomas
having gigantism, which contrasts strongly with 6.5%
among controls. This latter figure in the non-AIPmut con-
trol group is itself suggestive that gigantismmay not be as
rare as previously thought. Gigantism occurred in a fa-
milial setting in 63% of AIPmut cases in this series, al-
though therewere nine apparently sporadic giants. In con-
trast, Leontiou et al. (17) found no AIPmut cases among
seven sporadic giants, although gigantism did appear to
occur frequently among their FIPA kindreds. The likely
explanation for the high frequency of gigantism in the
setting of AIPmut is due to the common features of large
somatotropinomas secreting high levels of GH that be-
come symptomatic predominantly before epiphyseal
closure.
A pronounced gender imbalance was seen in the AIP-
mut cohort with about two thirds of patients being male.
This gender imbalance was marked in the prolactinoma
group, which was 76.9% male. These patients had large
tumors, half of which were not controlled by dopamine
agonists, and some were difficult to control with multiple
surgeries and radiotherapy. Male sex is known to be as-
sociated with a higher rate of aggressive or treatment-
resistant prolactinomas, andAIPmut statusmight explain
a proportion of such cases (35, 36). Overall, the male
preponderance among this series differs markedly from
the pituitary disease characteristics inMEN1, inwhich the
gender balance is reversed (69% female) (37). This differ-
ence may be due to the fact that prolactinomas comprise
62%of pituitary tumors inMEN1 and are 2.5 timesmore
frequent in women (37). Interestingly, prolactinomas in
MEN1 patients are, like the AIPmut cases, also compar-
atively difficult to treat. CNC is, in general, a disease with
a strong female preponderance (63%) (38). Although ac-
romegaly is a recognized phenotypic component of CNC,
it is relatively uncommon, occurring in only 42 patients
(12%) in the largest series,making valid comparisonswith
AIPmut patients difficult.
The penetrance of the pituitary adenoma predisposi-
tion conferred by AIPmut remains an unresolved ques-
tion. Based on current figures (there are100 asymptom-
atic AIPmut carriers related to patients in this study), the
penetrance of pituitary adenoma among FIPA kindreds
with AIPmut is 15–45%. This incomplete penetrance
stands indirect contrast toMEN1andCNC.Becausemost
AIPmut-related pituitary adenomas (87.5%) present be-
fore the age of 40 yr, many younger AIPmut carriers will
require extended follow-up to definitively determine pen-
etrance. Current penetrance rates suffer from various
sources of bias, such as small kindreds with limited avail-
ability for genetic and clinical evaluation, in addition to
apparently sporadic patients in whom family AIP genetic
testingwas not possible. True de novo sporadic cases have
been identified (18). As demonstrated by large, apparently
extensive multigenerational families in Finland, Italy, and
elsewhere,mutation foundersmayhave lived in thedistant
past (10, 39–41); this suggests that AIPmut status does
not greatly impair biological fitness, unlike in more ag-
gressive genetic tumor syndromes (42). It remains to be
determined whether some AIPmut confer a lower disease
penetrance than others.
Another important feature is the almost uniformly
early age at onset and the rapid growth characteristics in
AIPmut pituitary adenomas. The fact that more than half
of patients present already with extensive pituitary mac-
roadenomas as children or adolescents suggest that AIP-
mut status confers apredisposition to rapid tumorgrowth,
a point underlined by the short time from first symptoms
to diagnosis (2.0 yr). It is unclear whether loss of the wild-
type AIP allele in pituitary tissue itself leads to pituitary
adenoma development or whether this somatic second hit
permits rapid expansion of preexisting nests of abnormal
cells (e.g. hyperplastic zones). It remains to be determined
whether other modulating factors exist that can alter the
development of pituitary adenomas among AIPmut car-
riers. Furthermore, AIPmut-related disease in humans re-
mains limited to a pituitary adenoma phenotype, which
contrasts strongly with other genetic causes of pituitary
adenomas (MEN1, MEN4, CNC), which tend to affect
multiple tissues. Pituitary data from Ara9 knockout mice
models have not yet been reported (43, 44). Few data are
available on the molecular effects of AIPmut in the pi-
tuitary itself, and it remains unclear whether the pri-
marymechanism governing tumorigenesis is via the aryl
hydrocarbon receptor (AhR), down-regulation of AhR
nuclear translocator (45), interactions with phosphodi-
esterases (17), or via RET-survivin (46). Recent immu-
nohistochemical data indicate that AIP expression is high
in somatotropinomas and nonsecreting tumors (17, 47).
In somatotropinomas, however, significantly lower AIP im-
munostaining occurs in invasive as comparedwith noninva-
sive cases. Furthermore, AIP immunostainingwas abolished
inonlyaminorityofAIPmutpituitaryadenomas(46). Itmay
be that decreases in AIP immunostaining is a feature of ag-
gressiveness in somatotropinomas, irrespective of mutation
status.
Conclusions
AIPmut status is associated with the development of
anterior pituitary adenomas, and all pituitary tumor phe-
notypes have now been described, usually in a familial
setting. AIPmut-related pituitary adenomas are generally
large and expansive, and more than half are invasive at
diagnosis. Patients are predominantly male and young,
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with half of cases presenting during childhood or adoles-
cence. Somatotropinomas are encountered most fre-
quently (nearly 80%) and gigantism is notably frequent.
AIPmut-associated somatotropinomas are significantly
larger, more commonly extensive, occur at a younger age,
secrete higher levels of GH, and have more frequent pro-
lactin cosecretion than matched acromegalic patients
without AIPmut. AIPmut somatotropinomas require re-
peat surgery significantly more often than controls,
whereas hormonal and tumor responses to SSA are sig-
nificantly lower than controls; an increased risk of hypop-
ituitarism is seen in the AIPmut cohort. AIPmut-related
prolactinomas appear also to have aggressive and diffi-
cult-to-treat clinical characteristics.
These results suggest that improving outcomes among
AIPmut-associated pituitary tumors might require earlier
diagnosis at the microadenoma or enclosed macroad-
enoma stage. This adds impetus to exploring the most
appropriateway to identifyAIPmutpatients,whichmight
be aided by considering genetic screening only in FIPA
kindreds and young patients with large tumors (48).
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